Molecular Genetics and Metabolism
Volume 98, Issue 3, November 2009, Pages 319-321

doi:10.1016/j.ymgme.2009.07.001 | How to Cite or Link Using DOI
Copyright © 2009 Elsevier Inc. All rights reserved.

Brief Communication

Desensitization of an adult patient with Pompe disease and a history of anaphylaxis to alglucosidase alfa

Shawn E. Lipinski, Michael J. Lipinski, Autumn Burnette, Thomas A. Platts-Mills and William G. Wilson

aDivision of Medical Genetics, Department of Pediatrics, University of Virginia Health System, Charlottesville, VA, USA
bDepartment of Internal Medicine, University of Virginia Health System, Charlottesville, VA, USA
cAsthma and Allergic Diseases Center, University of Virginia Health System, Charlottesville, VA, USA

Received 25 April 2009; revised 1 July 2009; accepted 1 July 2009. Available online 7 July 2009.

Abstract
We report on the successful desensitization of an adult female with Pompe disease who had previously experienced anaphylaxis to intravenous alglucosidase alfa therapy. The starting alglucosidase alfa dose for desensitization was 10 mg/kg with gradual dose escalation and desensitization via serial dilution was completed over five infusions. This methodology serves as a means to desensitize patients with prior anaphylactic response to alglucosidase alfa so that enzyme replacement therapy can be utilized.

Keywords: Pompe disease; Enzyme replacement therapy; Lysosomal storage disease; Anaphylaxis; Allergy

Abstract
We report on the successful desensitization of an adult female with Pompe disease who had previously experienced anaphylaxis to intravenous alglucosidase alfa therapy. The starting alglucosidase alfa dose for desensitization was 10 mg/kg with gradual dose escalation and desensitization via serial dilution was completed over five infusions. This methodology serves as a means to desensitize patients with prior anaphylactic response to alglucosidase alfa so that enzyme replacement therapy can be utilized.

Keywords: Pompe disease; Enzyme replacement therapy; Lysosomal storage disease; Anaphylaxis; Allergy

Article Outline

Introduction
Patient history
Discussion
References

Statement of disclosure: The University of Virginia’s Division of Medical Genetics receives grants for educational funding from Genzyme Corporation.

Corresponding author. Address: University of Virginia Health System, Department of Pediatrics, Division of Medical Genetics, P.O. Box 800386, Charlottesville, VA 22908-0386, USA. Fax: +1 434 924 1797.